BioCentury
ARTICLE | Company News

Astellas sales and marketing update

February 11, 2013 8:00 AM UTC

Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012 that it launched three products. Astellas said that in January it launched Argamate Granule calcium polystyrene sulfonate with partner Sanwa Kagaku Kenkyusho Co. Ltd. (Nagoya, Japan) in Japan to treat hyperkalemia. The companies partnered in February 2012 to co-promote the product, which consist of Sanwa's Argamate calcium polystyrene sulfonate jelly and Astellas' bixalomer (see BioCentury, Feb. 27, 2012).

In October, the company launched in Japan its Quattrovac combination vaccine to prevent pertussis, diphtheria, tetanus and polio. The vaccine is a combination of adsorbed purified pertussis diphtheria tetanus combined vaccine (DPT vaccine) from Kaketsuken (Kumamoto, Japan) and inactivated poliomyelitis vaccine derived from purified polio viruses cultured in Vero cells from the Japan Poliomyelitis Research Institute. ...